{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:02:10Z","timestamp":1773806530157,"version":"3.50.1"},"reference-count":144,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.ctrv.2012.02.007","type":"journal-article","created":{"date-parts":[[2012,3,6]],"date-time":"2012-03-06T09:24:32Z","timestamp":1331025872000},"page":"877-889","source":"Crossref","is-referenced-by-count":42,"title":["Seed, soil and secreted hormones: Potential interactions of breast cancer cells with their endocrine\/paracrine microenvironment and implications for treatment with bisphosphonates"],"prefix":"10.1016","volume":"38","author":[{"given":"C.","family":"Wilson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Holen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.E.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2012.02.007_b0005","first-page":"98","article-title":"The distribution of secondary growths in cancer of the breast. 1889","volume":"8","author":"Paget","year":"1989","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ctrv.2012.02.007_b0010","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10555-006-9036-9","article-title":"Bone marrow cells in the \u2018pre-metastatic niche\u2019: within bone and beyond","volume":"25","author":"Kaplan","year":"2006","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ctrv.2012.02.007_b0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2004.06.010","article-title":"Molecular characterization of the tumor microenvironment in breast cancer","volume":"6","author":"Allinen","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2012.02.007_b0020","series-title":"Handbook of cancer-related bone disease","first-page":"35","article-title":"Pathophysiology of bone metastasis","author":"Holen","year":"2010"},{"key":"10.1016\/j.ctrv.2012.02.007_b0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1172\/JCI41004","article-title":"The therapeutic promise of the cancer stem cell concept","volume":"120","author":"Frank","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2012.02.007_b0030","doi-asserted-by":"crossref","first-page":"7843","DOI":"10.1158\/0008-5472.CAN-06-1010","article-title":"Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor","volume":"66","author":"Bao","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.007_b0035","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1749-6632.2009.04568.x","article-title":"Antitumor immunity and cancer stem cells","volume":"1176","author":"Schatton","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ctrv.2012.02.007_b0040","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1073\/pnas.1331931100","article-title":"From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression","volume":"100","author":"Schmidt-Kittler","year":"2003","journal-title":"Proc Nat Acad Sci USA"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2012.02.007_b0045","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/S0305-7372(97)90009-8","article-title":"Management of bone metastases","volume":"23","author":"Coleman","year":"1997","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2012.02.007_b0050","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0002-9440(10)65628-3","article-title":"Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases","volume":"153","author":"Luzzi","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ctrv.2012.02.007_b0055","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BD-2007-26106","article-title":"Priming the \u2018soil\u2019 for breast cancer metastasis: the pre-metastatic niche","volume":"26","author":"Psaila","year":"2006","journal-title":"Breast Dis"},{"key":"10.1016\/j.ctrv.2012.02.007_b0060","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nature04186","article-title":"VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche","volume":"438","author":"Kaplan","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2012.02.007_b0065","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nrc1877","article-title":"Fibroblasts in cancer","volume":"6","author":"Kalluri","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2012.02.007_b0070","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cell.2005.02.034","article-title":"Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1\/CXCL12 secretion","volume":"121","author":"Orimo","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2012.02.007_b0075","doi-asserted-by":"crossref","first-page":"6028","DOI":"10.1073\/pnas.88.14.6028","article-title":"Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression","volume":"88","author":"Cornil","year":"1991","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/j.ctrv.2012.02.007_b0080","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2012.02.007_b0085","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/0008-5472.CAN-05-4005","article-title":"Distinct role of macrophages in different tumor microenvironments","volume":"66","author":"Lewis","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.007_b0090","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/sj.bjc.6602901","article-title":"Macrophages promote angiogenesis in human breast tumour spheroids in vivo","volume":"94","author":"Bingle","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.007_b0095","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2012.02.007_b0100","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2012.02.007_b0105","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1546::AID-CNCR4>3.0.CO;2-I","article-title":"Mechanisms of bone metastasis","volume":"80","author":"Mundy","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2012.02.007_b0110","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/1535-7163.MCT-07-0234","article-title":"Molecular biology of bone metastasis","volume":"6","author":"Kingsley","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2012.02.007_b0115","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/onc.2008.454","article-title":"Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone","volume":"28","author":"Mourskaia","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2012.02.007_b0120","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1023\/A:1025462417256","article-title":"Breast cancer micrometastases: different interactions of carcinoma cells with normal and cancer patients\u2019 bone marrow stromata","volume":"20","author":"Nicola","year":"2003","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ctrv.2012.02.007_b0125","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/nature04957","article-title":"The stem-cell niche as an entity of action","volume":"441","author":"Scadden","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2012.02.007_b0130","first-page":"205","article-title":"Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention","volume":"2","author":"Lipton","year":"2004","journal-title":"J Support Oncol"},{"key":"10.1016\/j.ctrv.2012.02.007_b0135","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.007_b0140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1749-6632.2010.05766.x","article-title":"The use of bisphosphonates in cancer treatment","volume":"1218","author":"Coleman","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ctrv.2012.02.007_b0145","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.2174\/138161210791034003","article-title":"Bisphosphonates as treatment of bone metastases","volume":"16","author":"Holen","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ctrv.2012.02.007_b0150","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/CCO.0b013e328331c794","article-title":"Bisphosphonates in breast cancer: teaching an old dog new tricks","volume":"21","author":"Winter","year":"2009","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.007_b0155","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/SPC.0b013e3283499c93","article-title":"Adjuvant therapy with bone-targeted agents","volume":"5","author":"Wilson","year":"2011","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.ctrv.2012.02.007_b0160","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up","volume":"19","author":"Diel","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2012.02.007_b0165","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.007_b0170","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/02841860410032885","article-title":"Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients","volume":"43","author":"Saarto","year":"2004","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2012.02.007_b0175","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/sj.bjc.6603661","article-title":"Meta-analysis of clodronate and breast cancer survival","volume":"96","author":"Ha","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.007_b0180","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ejca.2009.12.003","article-title":"Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer","volume":"46","author":"McCloskey","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.007_b0185","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2010.31.5069","article-title":"Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA. 14","volume":"29","author":"Lipton","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.02.007_b0190","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2012.02.007_b0195","article-title":"The carry-over effect of adjuvant zoledronic acid: comparison of 48- and 62-month analyses of ABCSG-12 suggests that the benefits of combining zoledronic acid with adjuvant endocrine therapy persist long after completion of therapy","author":"Gnant","year":"2010","journal-title":"SABCS"},{"key":"10.1016\/j.ctrv.2012.02.007_b0200","doi-asserted-by":"crossref","unstructured":"Coleman RE, Thorpe HC, Cameron D et al. Adjuvant treatment with zoledronic acid in stage II\/III breast cancer. The AZURE trial (BIG 01\/04). San Antonio Breast Cancer Symposium, December 2010.","DOI":"10.1158\/0008-5472.SABCS10-S4-5"},{"key":"10.1016\/j.ctrv.2012.02.007_b0205","article-title":"NSABP Protocol B-34: a clinical trial comparing adjuvant clodronate vs placebo in early stage breast cancer patients receiving systemic chemotherapy and\/or tamoxifen or no therapy-final analysis","author":"Paterson","year":"2011","journal-title":"SABCS"},{"key":"10.1016\/j.ctrv.2012.02.007_b0210","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","article-title":"Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2012.02.007_b0215","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/cr.2008.323","article-title":"Roles of TGF-beta family signaling in stem cell renewal and differentiation","volume":"19","author":"Watabe","year":"2009","journal-title":"Cell Res"},{"key":"10.1016\/j.ctrv.2012.02.007_b0220","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cytogfr.2009.11.008","article-title":"Transforming growth factor beta (TGF-beta) and inflammation in cancer","volume":"21","author":"Bierie","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.ctrv.2012.02.007_b0225","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1042\/BJ20100427","article-title":"Regulation of TGF-beta signalling by protein phosphatases","volume":"430","author":"Liu","year":"2010","journal-title":"Biochem J"},{"key":"10.1016\/j.ctrv.2012.02.007_b0230","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1677\/ERC-09-0273","article-title":"Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis?","volume":"17","author":"Alarmo","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2012.02.007_b0235","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/jcb.20928","article-title":"Pro-metastasis function of TGFbeta mediated by the Smad pathway","volume":"98","author":"Kang","year":"2006","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.ctrv.2012.02.007_b0240","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1023\/A:1009568532177","article-title":"TGF-beta signaling in mammary gland development and tumorigenesis","volume":"6","author":"Wakefield","year":"2001","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"10.1016\/j.ctrv.2012.02.007_b0245","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.gde.2010.12.004","article-title":"Switching TGFbeta from a tumor suppressor to a tumor promoter","volume":"21","author":"Inman","year":"2011","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.ctrv.2012.02.007_b0250","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1155\/2009\/529253","article-title":"Variations in serum transforming growth factor-beta1 levels with gender, age and lifestyle factors of healthy Japanese adults","volume":"27","author":"Lin","year":"2009","journal-title":"Dis Markers"},{"key":"10.1016\/j.ctrv.2012.02.007_b0255","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1210\/endo-128-3-1682","article-title":"Evidence for an autocrine role of activin B within rat anterior pituitary cultures","volume":"128","author":"Corrigan","year":"1991","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2012.02.007_b0260","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1196\/annals.1315.023","article-title":"Activins and inhibins and their signaling","volume":"1038","author":"Vale","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ctrv.2012.02.007_b0265","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1073\/pnas.85.1.247","article-title":"Gonadal and extragonadal expression of inhibin alpha, beta A, and beta B subunits in various tissues predicts diverse functions","volume":"85","author":"Meunier","year":"1988","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/j.ctrv.2012.02.007_b0270","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mce.2009.07.001","article-title":"Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, activin and inhibin","volume":"310","author":"Nicks","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ctrv.2012.02.007_b0275","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.mce.2004.07.008","article-title":"The role of activin, follistatin and inhibin in testicular physiology","volume":"225","author":"de Kretser","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ctrv.2012.02.007_b0280","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3109\/1354750X.2010.495786","article-title":"Follistatin as a potent regulator of bone, metabolism","volume":"15","author":"Gajos-Michniewicz","year":"2010","journal-title":"Biomarkers"},{"key":"10.1016\/j.ctrv.2012.02.007_b0285","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/jcp.22272","article-title":"And bone metastasis","volume":"225","author":"Leto","year":"2010","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ctrv.2012.02.007_b0290","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.fertnstert.2006.12.009","article-title":"Differential effects of aging on activin A and its binding protein, follistatin, across the menopause transition","volume":"88","author":"Reame","year":"2007","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ctrv.2012.02.007_b0295","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1530\/eje.0.1390469","article-title":"Activin: an endocrine or paracrine agent?","volume":"139","author":"Welt","year":"1998","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ctrv.2012.02.007_b0300","first-page":"630","article-title":"Immunoradiometric assay for follistatin: serum immunoreactive follistatin levels in normal adults and pregnant women","volume":"81","author":"Wakatsuki","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.02.007_b0305","series-title":"Clinical medicine","author":"Clark","year":"1998"},{"key":"10.1016\/j.ctrv.2012.02.007_b0310","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMra000471","article-title":"Production and actions of estrogens","volume":"346","author":"Gruber","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2012.02.007_b0315","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1067\/mjd.2001.117432","article-title":"Estrogen production and action","volume":"45","author":"Nelson","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ctrv.2012.02.007_b0320","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.steroids.2010.01.012","article-title":"Analysis of estrogens in serum and plasma from postmenopausal women: past present, and future","volume":"75","author":"Blair","year":"2010","journal-title":"Steroids"},{"key":"10.1016\/j.ctrv.2012.02.007_b0325","first-page":"3328","article-title":"Changes in peripheral serum levels of total activin A during the human menstrual cycle and pregnancy","volume":"81","author":"Muttukrishna","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.02.007_b0330","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.tem.2009.11.009","article-title":"Inhibins: from reproductive hormones to tumor suppressors","volume":"21","author":"Stenvers","year":"2010","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.02.007_b0335","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/gme.0b013e3181735687","article-title":"A proposed classification system for menstrual cycles in the menopause transition based on changes in serum hormone profiles","volume":"15","author":"Robertson","year":"2008","journal-title":"Menopause"},{"key":"10.1016\/j.ctrv.2012.02.007_b0340","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.bpobgyn.2008.10.001","article-title":"Hormonal changes and biomarkers in late reproductive age, menopausal transition and menopause","volume":"23","author":"Hale","year":"2009","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.ctrv.2012.02.007_b0345","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/humupd\/dmm020","article-title":"A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women\u2019s Midlife Health Project","volume":"13","author":"Burger","year":"2007","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ctrv.2012.02.007_b0350","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1210\/jc.2003-031515","article-title":"Age-related analysis of inhibin A, inhibin B, and activin a relative to the intercycle monotropic follicle-stimulating hormone rise in normal ovulatory women","volume":"89","author":"Klein","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.02.007_b0355","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1046\/j.1365-2265.1998.00482.x","article-title":"Serum inhibins A and B fall differentially as FSH rises in perimenopausal women","volume":"48","author":"Burger","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ctrv.2012.02.007_b0360","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1210\/rp.57.1.257","article-title":"Hormonal changes in the menopause transition","volume":"57","author":"Burger","year":"2002","journal-title":"Recent Prog Horm Res"},{"key":"10.1016\/j.ctrv.2012.02.007_b0365","first-page":"105","article-title":"Female reproductive aging is marked by decreased secretion of dimeric inhibin","volume":"84","author":"Welt","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.02.007_b0370","first-page":"1151","article-title":"Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumor cell lines","volume":"6","author":"Kalkhoven","year":"1995","journal-title":"Cell Growth Differ"},{"key":"10.1016\/j.ctrv.2012.02.007_b0375","doi-asserted-by":"crossref","first-page":"18430","DOI":"10.1074\/jbc.M010768200","article-title":"The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin","volume":"276","author":"Cocolakis","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2012.02.007_b0380","doi-asserted-by":"crossref","first-page":"7968","DOI":"10.1158\/0008-5472.CAN-04-3553","article-title":"Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells","volume":"65","author":"Burdette","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.007_b0385","first-page":"3783","article-title":"Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer","volume":"63","author":"Jeruss","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.007_b0390","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1210\/jcem.87.5.8512","article-title":"Serum and tissue expression of activin a in postmenopausal women with breast cancer","volume":"87","author":"Reis","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.02.007_b0395","doi-asserted-by":"crossref","first-page":"7223","DOI":"10.1158\/0008-5472.CAN-07-0805","article-title":"Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth","volume":"67","author":"Razanajaona","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.007_b0400","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/bmj.296.6637.1621","article-title":"Growth factor expression in normal, benign, and malignant breast tissue","volume":"296","author":"Travers","year":"1988","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.ctrv.2012.02.007_b0405","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1172\/JCI200215333","article-title":"Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects","volume":"109","author":"Yang","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2012.02.007_b0410","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ijc.11494","article-title":"Expression of TGF-beta type II receptor antisense RNA impairs TGF-beta signaling in vitro and promotes mammary gland differentiation in vivo","volume":"107","author":"Lenferink","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.007_b0415","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0002-9440(10)63510-9","article-title":"Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation","volume":"163","author":"Gorska","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ctrv.2012.02.007_b0420","doi-asserted-by":"crossref","first-page":"8430","DOI":"10.1073\/pnas.0932636100","article-title":"Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis","volume":"100","author":"Siegel","year":"2003","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/j.ctrv.2012.02.007_b0425","doi-asserted-by":"crossref","first-page":"8691","DOI":"10.1128\/MCB.23.23.8691-8703.2003","article-title":"Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1","volume":"23","author":"Muraoka","year":"2003","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2012.02.007_b0430","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1158\/0008-5472.CAN-07-5597","article-title":"Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment","volume":"68","author":"Bierie","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.007_b0435","first-page":"497","article-title":"Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study","volume":"62","author":"Xie","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.007_b0440","first-page":"2613","article-title":"Prognostic significance of TGFbeta-1 and pSmad2\/3 in breast cancer patients with T1-2,N0 tumours","volume":"27","author":"Koumoundourou","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2012.02.007_b0445","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF01806496","article-title":"Expression and localization of inhibin\/activin subunits and activin receptors in MCF-7 cells, a human breast cancer cell line","volume":"37","author":"Ying","year":"1996","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2012.02.007_b0450","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.mce.2011.04.014","article-title":"Betaglycan: a multifunctional accessory","volume":"339","author":"Bilandzic","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ctrv.2012.02.007_b0455","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.1210\/en.2007-0155","article-title":"Transforming growth factor-beta blocks inhibin binding to different target cell types in a context-dependent manner through dual mechanisms involving betaglycan","volume":"148","author":"Farnworth","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2012.02.007_b0460","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s12307-011-0075-6","article-title":"TGF-beta in the bone microenvironment: role in breast cancer metastases","volume":"4","author":"Buijs","year":"2011","journal-title":"Cancer Microenviron"},{"key":"10.1016\/j.ctrv.2012.02.007_b0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-4644(2000)77:34+<1::AID-JCB2>3.0.CO;2-G","article-title":"Hormonal approach to breast cancer prevention","volume":"34","author":"Russo","year":"2000","journal-title":"J Cell Biochem Suppl"},{"key":"10.1016\/j.ctrv.2012.02.007_b0470","first-page":"81","article-title":"Inhibin\/activin subunits (inhibin-alpha, -betaA and -betaB) are differentially expressed in human breast cancer and their metastasis","volume":"13","author":"Mylonas","year":"2005","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2012.02.007_b0475","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1677\/ERC-07-0054","article-title":"Activin and estrogen crosstalk regulates transcription in human breast cancer cells","volume":"14","author":"Burdette","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2012.02.007_b0480","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/path.1785","article-title":"First evidence supporting a potential role for the BMP\/SMAD pathway in the progression of oestrogen receptor-positive breast cancer","volume":"206","author":"Helms","year":"2005","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2012.02.007_b0485","doi-asserted-by":"crossref","first-page":"14747","DOI":"10.1074\/jbc.M109.093039","article-title":"Estrogen inhibits transforming growth factor beta signaling by promoting Smad2\/3 degradation","volume":"285","author":"Ito","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2012.02.007_b0725","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/A:1006078032287","article-title":"Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast, cancer cells","volume":"51","author":"El Etreby","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2012.02.007_b0495","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/S0002-9440(10)61158-3","article-title":"Latent transforming growth factor-beta activation in mammary gland: regulation by ovarian hormones affects ductal and alveolar proliferation","volume":"160","author":"Ewan","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ctrv.2012.02.007_b0500","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1006\/excr.2001.5175","article-title":"Mechanisms of cell cycle arrest in response to TGF-beta in progestin-dependent and -independent growth of mammary tumors","volume":"265","author":"Salatino","year":"2001","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.ctrv.2012.02.007_b0505","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0039-128X(03)00138-7","article-title":"Risk of breast cancer with progestins: critical assessment of current data","volume":"68","author":"Santen","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.ctrv.2012.02.007_b0510","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1210\/jc.2009-2509","article-title":"Postmenopausal hormone therapy: an Endocrine Society scientific statement","volume":"95","author":"Santen","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.02.007_b0515","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1210\/jc.2008-0938","article-title":"Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis","volume":"93","author":"Horwitz","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.02.007_b0520","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1749-6632.2009.05349.x","article-title":"Bone turnover across the menopause transition: the role of gonadal inhibins","volume":"1192","author":"Nicks","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ctrv.2012.02.007_b0525","doi-asserted-by":"crossref","first-page":"14233","DOI":"10.1016\/S0021-9258(19)49702-0","article-title":"Bovine bone activin enhances bone morphogenetic protein-induced ectopic bone formation","volume":"267","author":"Ogawa","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2012.02.007_b0530","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1210\/endo.143.1.8580","article-title":"Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures","volume":"143","author":"Gaddy-Kurten","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2012.02.007_b0535","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1096\/fj.07-8080com","article-title":"The activin A-follistatin system: potent regulator of human extracellular matrix mineralization","volume":"21","author":"Eijken","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.ctrv.2012.02.007_b0540","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/jcb.10613","article-title":"Activin A stimulates IkappaB-alpha\/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors","volume":"90","author":"Sugatani","year":"2003","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.ctrv.2012.02.007_b0545","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature02006","article-title":"Smad-dependent and Smad-independent pathways in TGF-beta family signalling","volume":"425","author":"pDerynck","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2012.02.007_b0550","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1002\/jbmr.142","article-title":"Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo","volume":"25","author":"Chantry","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2012.02.007_b0555","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/onc.2009.426","article-title":"Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis","volume":"29","author":"Petersen","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2012.02.007_b0560","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nm0709-729","article-title":"Coupling bone degradation to formation","volume":"15","author":"Iqbal","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2012.02.007_b0565","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/jbmr.139","article-title":"Inhibition of TGF-beta signaling by 1D11 antibody treatment increases bone mass and quality in vivo","volume":"25","author":"Edwards","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2012.02.007_b0570","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s12307-011-0075-6","article-title":"TGF-beta in the bone microenvironment: role in breast cancer metastases","volume":"4","author":"Buijs","year":"2011","journal-title":"Cancer Microenviron"},{"key":"10.1016\/j.ctrv.2012.02.007_b0575","doi-asserted-by":"crossref","first-page":"e6896","DOI":"10.1371\/journal.pone.0006896","article-title":"Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment","volume":"4","author":"Dunn","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2012.02.007_b0580","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1210\/jc.2005-2423","article-title":"Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone","volume":"91","author":"Perrien","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.02.007_b0585","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.bjc.6602824","article-title":"Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells","volume":"93","author":"Garvin","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.007_b0590","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/bjc.2011.348","article-title":"Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer","volume":"105","author":"Kaneda","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.007_b0595","first-page":"3351","article-title":"Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement","volume":"80","author":"Bismar","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2012.02.007_b0600","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1210\/endo.133.2.8393776","article-title":"Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal","volume":"133","author":"Passeri","year":"1993","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2012.02.007_b0605","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1387\/ijdb.113371dl","article-title":"Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions","volume":"55","author":"Laoui","year":"2011","journal-title":"Int J Dev Biol"},{"key":"10.1016\/j.ctrv.2012.02.007_b0610","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1593\/neo.10200","article-title":"Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms","volume":"12","author":"Hembruff","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.ctrv.2012.02.007_b0615","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1038\/sj.onc.1208685","article-title":"Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks","volume":"24","author":"Cheng","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2012.02.007_b0620","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2012.02.007_b0625","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.bone.2007.12.225","article-title":"Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells","volume":"42","author":"Coxon","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2012.02.007_b0630","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1359\/jbmr.091009","article-title":"Fluorescent risedronate analogs reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo","volume":"25","author":"Roelofs","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2012.02.007_b0635","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/jbmr.5650070507","article-title":"Retention of etidronate in human, dog, and rat","volume":"7","author":"Kasting","year":"1992","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2012.02.007_b0640","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00018-005-5298-6","article-title":"Isoprenylated proteins","volume":"63","author":"McTaggart","year":"2006","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ctrv.2012.02.007_b0645","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ctrv.2012.02.007_b0650","first-page":"3890","article-title":"Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices","volume":"57","author":"Boissier","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.007_b0655","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","article-title":"The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel","volume":"84","author":"Jagdev","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.007_b0660","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/ijc.20602","article-title":"Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells","volume":"113","author":"Neville-Webbe","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.007_b0665","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T","article-title":"Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone","volume":"83","author":"Magnetto","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.007_b0670","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.2174\/138161210793563590","article-title":"Combined therapies of bone disease with bisphosphonates","volume":"16","author":"Syddall","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ctrv.2012.02.007_b0675","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","article-title":"The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer","volume":"102","author":"Coleman","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2012.02.007_b0680","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.007_b0685","doi-asserted-by":"crossref","unstructured":"Winter MC SS, Cross SS et al. ANZAC: A randomised neoadjuvant biomarker study investigating the anti-tumour activity of the addition of zoledronic acid to chemotherapy in breast cancer. In: San Antonio Breast Cancer Symposium. San Antonio: 2010.","DOI":"10.1158\/0008-5472.SABCS10-P1-11-01"},{"key":"10.1016\/j.ctrv.2012.02.007_b0690","series-title":"Handbook of cancer related bone disease","first-page":"71","article-title":"Bisphosphonates: mechanisms of action","author":"Roelofs","year":"2010"},{"key":"10.1016\/j.ctrv.2012.02.007_b0695","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00262-008-0482-9","article-title":"Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages","volume":"57","author":"Tsagozis","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2012.02.007_b0700","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1359\/jbmr.091009","article-title":"Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo","volume":"25","author":"Roelofs","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2012.02.007_b0705","doi-asserted-by":"crossref","first-page":"11438","DOI":"10.1158\/0008-5472.CAN-07-1882","article-title":"Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma","volume":"67","author":"Melani","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.02.007_b0710","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S8756-3282(99)00268-9","article-title":"Activin release from bone coupled to bone resorption in organ culture of neonatal mouse calvaria","volume":"26","author":"Sakai","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.ctrv.2012.02.007_b0715","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/nm.1943","article-title":"Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis","volume":"15","author":"Korpal","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2012.02.007_b0720","first-page":"4025","article-title":"Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women","volume":"84","author":"Burger","year":"1999","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721200028X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721200028X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T15:58:46Z","timestamp":1641052726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573721200028X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":144,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S030573721200028X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2012.02.007","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}